<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22718" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hemicrania Continua</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hameed</surname>
            <given-names>Sajid</given-names>
          </name>
          <aff>Aga Khan University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharman</surname>
            <given-names>Tariq</given-names>
          </name>
          <aff>Southern Ohio Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sajid Hameed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tariq Sharman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22718.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hemicrania continua is a primary headache disorder with symptoms typically lasting at least 3 months. This condition falls under the category of primary headache disorders known as trigeminal autonomic cephalalgia syndromes. The headache is typically unilateral and associated with autonomic features, indicating overactivity of the parasympathetic system and decreased sympathetic system activity. Hemicrania continua's striking response to indomethacin&#x000a0;is a good diagnostic feature.</p>
        <p>Hemicrania continua adversely affects&#x000a0;patients' quality of life.&#x000a0;The condition presents clinically with a baseline continuous unilateral headache for months that intermittently exacerbates with associated autonomic features. Diagnosis involves clinical evaluation, where the distinctive features include a headache duration of at least 3 months and a good response to indomethacin. Neuroimaging tests may be&#x000a0;conducted to rule out other potential causes. Treatment for hemicrania continua primarily revolves around indomethacin, with medications such as celecoxib, topiramate, and gabapentin as potential alternatives for individuals who cannot tolerate indomethacin.&#x000a0;Regular follow-up is essential&#x000a0;to monitor symptoms and adjust treatment as necessary to manage pain effectively while minimizing adverse effects.</p>
        <p>This activity for healthcare professionals is designed to enhance learners' proficiency in evaluating and managing hemicrania cornua. Participants gain a broader grasp of the condition's&#x000a0;risk factors, clinical features, and best diagnostic and treatment practices. Enhanced competence enables learners to collaborate within an interprofessional team caring for individuals with&#x000a0;hemicrania continua, thus enhancing outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the typical clinical presentations of hemicrania continua.</p></list-item><list-item><p>Apply&#x000a0;the International Classification of Headache Disorders, 3rd edition's diagnostic criteria&#x000a0;when evaluating suspected&#x000a0;hemicrania continua.</p></list-item><list-item><p>Develop&#x000a0;personalized treatment strategies for individuals diagnosed with hemicrania continua.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients&#x000a0;with hemicrania continua.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22718&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22718">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22718.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hemicrania continua is a primary headache disorder with a pathognomonic treatment response to indomethacin.&#x000a0;The condition presents clinically with a baseline continuous unilateral headache for at least&#x000a0;3 months that intermittently exacerbates with associated autonomic features.&#x000a0;Hemicrania continua was first described in 1981 by Medina and Diamond as a variant of cluster headache.<xref ref-type="bibr" rid="article-22718.r1">[1]</xref> The term hemicrania continua was first coined in 1984 by Sjaastad and Spierings.<xref ref-type="bibr" rid="article-22718.r2">[2]</xref></p>
        <p>Hemicrania continua falls under the category of trigeminal autonomic cephalalgias in the&#x000a0;3rd edition of the International Classification of Headache Disorders (ICHD-3). The main features of trigeminal autonomic cephalalgias are unilateral headaches, occurring mainly in the area&#x000a0;innervated by the trigeminal nerve's ophthalmic division, associated with a variable combination of autonomic symptoms, reflecting&#x000a0;increased parasympathetic&#x000a0;and&#x000a0;decreased sympathetic activities.<xref ref-type="bibr" rid="article-22718.r3">[3]</xref> Other trigeminal autonomic cephalalgias include cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA), and short-lasting, unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT).<xref ref-type="bibr" rid="article-22718.r4">[4]</xref></p>
      </sec>
      <sec id="article-22718.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Hemicrania continua is a primary headache disorder without a secondary organic cause. Our understanding of the pathogenetic mechanisms of trigeminal autonomic cephalalgias, including hemicrania continua, is limited. Multiple theories have been proposed, including cavernous sinus inflammation, intracranial arterial vasodilation, upregulation of vasopeptides, particularly calcitonin gene&#x02013;related peptide and vasoactive intestinal peptide, and trigeminal nerve autonomic dysregulation, resulting in the increased cranial parasympathetic outflow. Other intracranial areas are also involved, as pain is not always restricted to the area supplied by the trigeminal nerve. Secondly, trigeminal nerve transection does not relieve symptoms in all patients.<xref ref-type="bibr" rid="article-22718.r5">[5]</xref></p>
      </sec>
      <sec id="article-22718.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Hemicrania continua was initially considered a rare headache disorder. Only 18 cases were reported in the first 7 years and about 100 cases in the first 17 years (1984-2001) after&#x000a0;its discovery.<xref ref-type="bibr" rid="article-22718.r6">[6]</xref><xref ref-type="bibr" rid="article-22718.r7">[7]</xref>&#x000a0;Although large epidemiologic studies are lacking to outline the exact prevalence of this condition, hemicrania continua cases are estimated to constitute about 1% of total headache cases.<xref ref-type="bibr" rid="article-22718.r8">[8]</xref><xref ref-type="bibr" rid="article-22718.r9">[9]</xref>&#x000a0;A more recent meta-analysis of patients attending headache clinics estimated a higher number of 1.8% among all headache patients.<xref ref-type="bibr" rid="article-22718.r10">[10]</xref> This number is still considered underreported and underdiagnosed.</p>
        <p>Hemicrania continua is more prevalent in young adults in their third and fourth decades, with a mean age of 30. However, the range varies from&#x000a0;the first to&#x000a0;seventh decades. Hemicrania continua is slightly more common in&#x000a0;women compared to men, with a reported female-to-male ratio of 1 to 2.4.<xref ref-type="bibr" rid="article-22718.r10">[10]</xref></p>
      </sec>
      <sec id="article-22718.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>As the name indicates, patients with hemicrania continua present with a continuous unilateral headache lasting at least 3 months.&#x000a0;This headache is mild to moderate in severity, dull in character, and often does not affect physical activity. The pain commonly coincides with the territories innervated by&#x000a0;the trigeminal nerve's first division,&#x000a0;particularly the frontal and periorbital regions, but extratrigeminal areas may also be involved.</p>
        <p>The unilateral headache in&#x000a0;hemicrania continua is side-locked, meaning it occurs on the same side, with a slight preference for the right side.&#x000a0;However, side-alternating attacks have also been reported in the literature.<xref ref-type="bibr" rid="article-22718.r11">[11]</xref>&#x000a0;Rare cases of bilateral hemicrania continua have also been documented.<xref ref-type="bibr" rid="article-22718.r12">[12]</xref><xref ref-type="bibr" rid="article-22718.r13">[13]</xref><xref ref-type="bibr" rid="article-22718.r14">[14]</xref> Although the headache in&#x000a0;hemicrania continua is unremitting, about 1 in 5 persons (20%) may experience pain-free periods lasting from&#x000a0;1 day to several weeks.<xref ref-type="bibr" rid="article-22718.r15">[15]</xref> The clinical diagnostic criteria&#x000a0;based on ICHD-3&#x000a0;are listed in the Evaluation section below.</p>
        <p>The background headache often has superimposed fluctuating headache exacerbations, lasting a few minutes to days. These exacerbations are also highly variable, with a frequency ranging from more than 20 attacks daily to&#x000a0;1 attack in 4 months. About half of patients report&#x000a0;1 attack daily.&#x000a0;The pain&#x000a0;is moderate to very severe in intensity and throbbing or stabbing in character.&#x000a0;Some people may label these headache exacerbations as the worst headache of their lives and may also experience suicidal thoughts during these exacerbations. Patients may become restless, agitated, and have difficulty staying still.</p>
        <p>The migrainous features of photophobia, phonophobia, nausea, and vomiting may occur during exacerbations, but aura is very uncommon.&#x000a0;Stress, alcohol, irregular sleep patterns, and menstruation also trigger exacerbations in some patients.</p>
        <p>Similar to&#x000a0;other trigeminal autonomic cephalalgias, hemicrania continua is associated with ipsilateral cranial autonomic symptoms, especially during exacerbations. Still, these autonomic symptoms are generally less prominent&#x000a0;compared to other trigeminal autonomic cephalalgias, including cluster headaches and paroxysmal hemicrania. The cranial autonomic features reflect parasympathetic overactivity and sympathetic underactivity. These features&#x000a0;may include forehead sweating, lacrimation, conjunctival injection and swelling, ptosis, miosis, foreign body sensation in the eye, nasal congestion, rhinorrhea, and aural fullness.</p>
      </sec>
      <sec id="article-22718.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>ICHD-3 has proposed the following criteria for the diagnosis of hemicrania continua:</p>
        <list list-type="bullet">
          <list-item>
            <p>Unilateral headache fulfilling criteria 2 to 4</p>
          </list-item>
          <list-item>
            <p>Present for greater than 3 months, with exacerbations of moderate or greater intensity</p>
          </list-item>
          <list-item>
            <p>Either or both of the following:
<list list-type="bullet"><list-item><p>At least&#x000a0;1 of the following symptoms or signs, ipsilateral to the headache:
<list list-type="bullet"><list-item><p>Conjunctival injection or lacrimation</p></list-item><list-item><p>Nasal congestion or rhinorrhoea</p></list-item><list-item><p>Eyelid edema</p></list-item><list-item><p>Forehead and facial sweating</p></list-item><list-item><p>Miosis or ptosis</p></list-item></list>
</p></list-item><list-item><p>A sense of restlessness or agitation or pain aggravation by movement</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Responds absolutely to therapeutic doses of indomethacin</p>
          </list-item>
          <list-item>
            <p>Not better accounted for by another ICHD-3 diagnosis</p>
          </list-item>
        </list>
        <p>The ICHD-3 diagnostic criteria for hemicrania continua focus on 3 key features: unilateral continuous pain for more than 3 months, the presence of either ipsilateral cranial autonomic symptoms or agitation during exacerbations, and a complete response to indomethacin, which is 1 of the pathognomonic features of hemicrania continua. A complete response to indomethacin is typically noted within 2 hours of indomethacin injection. The headache reappears within 6 to 24 hours of stopping indomethacin. Since indomethacin provides dramatic relief, an indomethacin trial is proposed by a few authors in all chronic unilateral headaches. However, a response to indomethacin does not rule out secondary causes of&#x000a0;hemicrania continua.<xref ref-type="bibr" rid="article-22718.r16">[16]</xref></p>
        <p>Secondary conditions that may mimic hemicrania continua include posttraumatic headache, post-craniotomy headache, intracranial space-occupying lesions, poststroke headache, internal carotid artery dissection or aneurysm, idiopathic intracranial hypertension, venous malformation, cerebral venous sinus thrombosis, analgesic rebound headache, paraneoplastic syndromes, sinus pathologies, dental lesions, and temporomandibular joint pathologies.</p>
        <p>Secondary causes of&#x000a0;hemicrania continua should be excluded based on clinical features and appropriate investigations. All patients should be asked about any history of recent trauma. Brain magnetic resonance imaging (MRI) is recommended&#x000a0;for all patients presenting with hemicrania continua&#x02013;like headaches.<xref ref-type="bibr" rid="article-22718.r17">[17]</xref>&#x000a0;An angiography, such as magnetic resonance,&#x000a0;computed tomography, or digital subtraction angiography, of the head and neck should be advised if a vascular pathology, such as&#x000a0;internal carotid artery dissection or aneurysm, is suspected.&#x000a0;The clinical features suggesting a vascular pathology include the short-term duration of symptoms, frequent exacerbations, neck pain, neck tenderness, focal neurological symptoms, Horner syndrome,&#x000a0;and&#x000a0;a history of trauma.</p>
      </sec>
      <sec id="article-22718.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Indomethacin</bold>
</p>
        <p>A complete response to indomethacin is 1 of the pathognomonic features of hemicrania continua. Indomethacin is a nonsteroidal anti-inflammatory drug that reversibly inhibits prostaglandin-forming cyclooxygenase (COX) enzyme, similar to ibuprofen and naproxen. Indomethacin is more effective compared to other nonsteroidal anti-inflammatory drugs, probably&#x000a0;because it exhibits&#x000a0;the&#x000a0;greatest central nervous system penetration, central serotonergic effects, inhibition of nitrous oxide-dependent vasodilation, and effects unrelated to COX inhibition.<xref ref-type="bibr" rid="article-22718.r18">[18]</xref> Indomethacin may abort an acute exacerbation of&#x000a0;hemicrania continua.&#x000a0;This drug is also effective in&#x000a0;hemicrania continua prophylaxis, another reason its effect may not be purely related to COX inhibition.<xref ref-type="bibr" rid="article-22718.r19">[19]</xref></p>
        <p>Indomethacin is started at a low dose of 25 mg 3 times a day with meals and titrated slowly, depending upon the response. Patients typically respond within 24 hours, but some may take up to a week.<xref ref-type="bibr" rid="article-22718.r20">[20]</xref>&#x000a0;If no clinical response is observed within 48 to 72 hours,&#x000a0;the dose is typically increased until either a complete response is achieved or a maximum dose of 500 mg/d is given. The mean dose is typically lower than 200 mg/d.</p>
        <p>Keeping the patient on a minimal long-term therapeutic dose of&#x000a0;indomethacin is&#x000a0;reasonable to mitigate potential adverse effects, including abdominal discomfort, heartburn, nausea, vomiting, life-threatening gastrointestinal hemorrhage, hypertension, renal failure, and liver failure. Most of the adverse effects of indomethacin are dose-dependent, and maintaining the lowest possible therapeutic dose is recommended. The treatment is often long-term, if not lifelong. Successful indomethacin tapering&#x000a0;has been reported in multiple patients without headache recurrence.</p>
        <p>
<bold>Other Noninvasive Treatments</bold>
</p>
        <p>Other noninvasive treatment options should be tried if a patient cannot tolerate indomethacin due to its side effects. These alternatives include melatonin; topiramate; COX-2 inhibitors, such as rofecoxib and celecoxib; gabapentin; corticosteroids; lamotrigine; lithium; amitriptyline; valproate; and naproxen. These drugs are not as effective as indomethacin for treating hemicrania continua, but they should be tried before invasive interventional options are considered. Melatonin has a structure similar to indomethacin and&#x000a0;may also be combined with the nonsteroidal anti-inflammatory drug to lower the latter's dose and prevent&#x000a0;adverse effects.<xref ref-type="bibr" rid="article-22718.r21">[21]</xref>&#x000a0;High-dose oxygen and sumatriptan are typically not effective in&#x000a0;managing hemicrania continua. A calcitonin gene&#x02013;related peptide inhibitor, galcanezumab, has been reported to be successful in aborting pain&#x000a0;in patients with&#x000a0;hemicrania continua.<xref ref-type="bibr" rid="article-22718.r22">[22]</xref></p>
        <p>
<bold>Invasive Treatments</bold>
</p>
        <p>Vagus nerve stimulation is&#x000a0;an invasive neuromodulation technique used to treat hemicrania continua. Although available data&#x000a0;are limited, a positive response has been reported in some studies.<xref ref-type="bibr" rid="article-22718.r23">[23]</xref><xref ref-type="bibr" rid="article-22718.r24">[24]</xref></p>
        <p>Botulinum toxin-A is a treatment approved by the Food and Drug Administration for chronic migraines. Many clinicians also consider it for&#x000a0;treating hemicrania continua when noninvasive treatment fails or cannot be tolerated.<xref ref-type="bibr" rid="article-22718.r25">[25]</xref></p>
        <p>Occipital nerve stimulation,&#x000a0;such as botulinum toxin, is primarily used for resistant cases of chronic migraine.&#x000a0;This modality is currently being investigated for treating hemicrania continua with varying results.<xref ref-type="bibr" rid="article-22718.r26">[26]</xref><xref ref-type="bibr" rid="article-22718.r27">[27]</xref><xref ref-type="bibr" rid="article-22718.r28">[28]</xref></p>
        <p>Sphenopalatine ganglion blockade is another invasive treatment used for managing hemicrania continua. This intervention&#x000a0;cuts the parasympathetic outflow of the trigeminal nerve, an important pathophysiologic response in patients with hemicrania continua.</p>
        <p>Deep brain stimulation is another&#x000a0;invasive method&#x000a0;that may be used to treat medically refractory trigeminal autonomic cephalalgia, including hemicrania continua. The posterior&#x000a0;hypothalamus is the target in patients undergoing this treatment.<xref ref-type="bibr" rid="article-22718.r29">[29]</xref></p>
      </sec>
      <sec id="article-22718.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of hemicrania continua includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Secondary hemicrania continua, as outlined above,&#x000a0;including ophthalmic herpes zoster&#x000a0;<xref ref-type="bibr" rid="article-22718.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Chronic migraine</p>
          </list-item>
          <list-item>
            <p>Cluster headache</p>
          </list-item>
          <list-item>
            <p>Paroxysmal hemicrania</p>
          </list-item>
          <list-item>
            <p>Medication-overuse headache</p>
          </list-item>
        </list>
        <p>A meticulous clinical investigation and appropriate use of diagnostic tests can differentiate these conditions and determine the best treatment option.</p>
      </sec>
      <sec id="article-22718.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Hemicrania continua is not life-threatening, although it is often a lifelong condition. Chronic headaches, even treatable ones, affect patients' quality of life. A complete response to indomethacin treatment is&#x000a0;1 of the pathognomonic features of this condition.</p>
      </sec>
      <sec id="article-22718.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Most complications of&#x000a0;hemicrania continua are treatment-related. Most patients require long-term indomethacin treatment and are thus at risk of developing adverse effects, including abdominal discomfort, heartburn, nausea, vomiting, life-threatening gastrointestinal hemorrhage, hypertension, and renal and liver failure.</p>
      </sec>
      <sec id="article-22718.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated about the benign and chronic nature of this disease. This condition is treatable, but long-term treatment is typically warranted. Predisposing factors&#x000a0;to headache exacerbations, if known, should be avoided. Physical exercise should be encouraged. Regular follow-up is recommended to ensure proper medication intake and minimize adverse&#x000a0;effects.</p>
      </sec>
      <sec id="article-22718.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>The most important points to remember when evaluating and managing hemicrania continua are the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hemicrania continua&#x000a0;features a unilateral continuous headache lasting&#x000a0;at least&#x000a0;3 months&#x000a0;and may have episodic headache exacerbations.</p>
          </list-item>
          <list-item>
            <p>Ipsilateral cranial autonomic symptoms are typically present.</p>
          </list-item>
          <list-item>
            <p>Agitation and restlessness may occur during exacerbations.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The diagnosis of hemicrania continua is clinical, guided by ICHD-3 criteria. One of the pathognomonic features of hemicrania continua is a complete response to indomethacin.</p>
          </list-item>
          <list-item>
            <p>Hemicrania continua is a rare yet often lifelong condition.&#x000a0;A response to indomethacin does not exclude secondary causes of the condition, which should be&#x000a0;ruled out&#x000a0;by proper history, examination, and investigations that include at least a&#x000a0;brain MRI with contrast studies and an angiogram.<xref ref-type="bibr" rid="article-22718.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Indomethacin is the treatment of choice, though&#x000a0;alternatives&#x000a0;may be offered to&#x000a0;patients with contraindications or intolerance to this nonsteroidal anti-inflammatory drug.</p>
          </list-item>
        </list>
        <p>Patient counseling must emphasize the condition's benign nature and the importance of trigger factor avoidance&#x000a0;and regular follow-up.</p>
      </sec>
      <sec id="article-22718.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A neurologist typically diagnoses hemicrania continua and outlines appropriate treatment strategies. Given that hemicrania continua is a chronic condition that can persist for a lifetime, its management often requires ongoing care and adjustment of treatment plans. During periods of severe headache exacerbations, patients may experience significant emotional distress, including depressive episodes and suicidal tendencies. This psychological impact underscores the importance of screening all patients with hemicrania continua for mental health issues. Referring patients to psychiatrists and psychotherapists is essential for addressing these mental health concerns, providing support, and improving overall well-being.</p>
        <p>A coordinated, interprofessional approach to patient care can greatly enhance health outcomes for individuals with hemicrania continua. This approach typically involves collaboration among several healthcare professionals, such as primary care physicians who manage overall health and coordinate care, neurologists who focus on the neurological aspects of the condition, psychiatrists who address mental health concerns, psychotherapists who offer counseling and therapy, and pharmacists who assist with medication management. By integrating the expertise of these professionals, a comprehensive care plan can be developed that addresses both the physical and psychological aspects of hemicrania continua, ultimately improving patient outcomes and quality of life.</p>
      </sec>
      <sec id="article-22718.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22718&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22718">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/migraine-headaches/hemicrania-continua/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22718">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22718/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22718">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22718.s15">
        <title>References</title>
        <ref id="article-22718.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Medina</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cluster headache variant. Spectrum of a new headache syndrome.</article-title>
            <source>Arch Neurol</source>
            <year>1981</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>11</issue>
            <fpage>705</fpage>
            <page-range>705-9</page-range>
            <pub-id pub-id-type="pmid">7305699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sjaastad</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Spierings</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>"Hemicrania continua": another headache absolutely responsive to indomethacin.</article-title>
            <source>Cephalalgia</source>
            <year>1984</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-70</page-range>
            <pub-id pub-id-type="pmid">6713526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bahra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Paroxysmal hemicrania and hemicrania continua: Review on pathophysiology, clinical features and treatment.</article-title>
            <source>Cephalalgia</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>43</volume>
            <issue>11</issue>
            <fpage>3331024231214239</fpage>
            <pub-id pub-id-type="pmid">37950675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <collab>Headache Classification Committee of the International Headache Society (IHS)</collab>
            <article-title>The International Classification of Headache Disorders, 3rd edition (beta version).</article-title>
            <source>Cephalalgia</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>629</fpage>
            <page-range>629-808</page-range>
            <pub-id pub-id-type="pmid">23771276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barloese</surname>
                <given-names>MCJ</given-names>
              </name>
            </person-group>
            <article-title>The pathophysiology of the trigeminal autonomic cephalalgias, with clinical implications.</article-title>
            <source>Clin Auton Res</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>315</fpage>
            <page-range>315-324</page-range>
            <pub-id pub-id-type="pmid">28942483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prakash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hemicrania continua: clinical review, diagnosis and management.</article-title>
            <source>J Pain Res</source>
            <year>2017</year>
            <volume>10</volume>
            <fpage>1493</fpage>
            <page-range>1493-1509</page-range>
            <pub-id pub-id-type="pmid">28721092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charlson</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Hemicrania continua.</article-title>
            <source>Curr Neurol Neurosci Rep</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>436</fpage>
            <pub-id pub-id-type="pmid">24452694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sjaastad</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bakketeig</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>The rare, unilateral headaches. V&#x000e5;g&#x000e5; study of headache epidemiology.</article-title>
            <source>J Headache Pain</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-27</page-range>
            <pub-id pub-id-type="pmid">17221345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bigal</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Rapoport</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Sheftell</surname>
                <given-names>FD</given-names>
              </name>
            </person-group>
            <article-title>Primary chronic daily headache and its subtypes in adolescents and adults.</article-title>
            <source>Neurology</source>
            <year>2004</year>
            <month>Sep</month>
            <day>14</day>
            <volume>63</volume>
            <issue>5</issue>
            <fpage>843</fpage>
            <page-range>843-7</page-range>
            <pub-id pub-id-type="pmid">15365134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Khazali</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Al-Khazali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iljazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Ashina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Ashina</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and clinical features of hemicrania continua in clinic-based studies: A systematic review and meta-analysis.</article-title>
            <source>Cephalalgia</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>3331024221131343</fpage>
            <pub-id pub-id-type="pmid">36588185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prakash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adroja</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Hemicrania Continua.</article-title>
            <source>Ann Indian Acad Neurol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>Suppl 1</issue>
            <fpage>S23</fpage>
            <page-range>S23-S30</page-range>
            <pub-id pub-id-type="pmid">29720815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasquier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leys</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Petit</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>"Hemicrania continua": the first bilateral case?</article-title>
            <source>Cephalalgia</source>
            <year>1987</year>
            <month>Sep</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>169</fpage>
            <page-range>169-70</page-range>
            <pub-id pub-id-type="pmid">3652198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iordanidis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sjaastad</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Hemicrania continua: a case report.</article-title>
            <source>Cephalalgia</source>
            <year>1989</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>301</fpage>
            <page-range>301-3</page-range>
            <pub-id pub-id-type="pmid">2611889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Southerland</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Login</surname>
                <given-names>IS</given-names>
              </name>
            </person-group>
            <article-title>Rigorously defined hemicrania continua presenting bilaterally.</article-title>
            <source>Cephalalgia</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>14</issue>
            <fpage>1490</fpage>
            <page-range>1490-2</page-range>
            <pub-id pub-id-type="pmid">21803934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cittadini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Hemicrania continua: a clinical study of 39 patients with diagnostic implications.</article-title>
            <source>Brain</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>133</volume>
            <issue>Pt 7</issue>
            <fpage>1973</fpage>
            <page-range>1973-86</page-range>
            <pub-id pub-id-type="pmid">20558416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>VanderPluym</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Indomethacin-responsive headaches.</article-title>
            <source>Curr Neurol Neurosci Rep</source>
            <year>2015</year>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>516</fpage>
            <pub-id pub-id-type="pmid">25467407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yildiz Goksel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bilgin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Digre</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cortez</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ozudogru</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>The critical role of neuroimaging in hemicrania continua: A&#x000a0;systematic review and case series.</article-title>
            <source>Headache</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>674</fpage>
            <page-range>674-684</page-range>
            <pub-id pub-id-type="pmid">38780233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Summ</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Andreou</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Akerman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches.</article-title>
            <source>J Headache Pain</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>477</fpage>
            <page-range>477-83</page-range>
            <pub-id pub-id-type="pmid">20978816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Indomethacin-Responsive Headache Disorders.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2024</year>
            <month>Apr</month>
            <day>01</day>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>488</fpage>
            <page-range>488-497</page-range>
            <pub-id pub-id-type="pmid">38568495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prakash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>ND</given-names>
              </name>
            </person-group>
            <article-title>Delayed response of indomethacin in patients with hemicrania continua: real or phantom headache?</article-title>
            <source>Cephalalgia</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>375</fpage>
            <page-range>375-9</page-range>
            <pub-id pub-id-type="pmid">19489876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chilakamarri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zubair</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kuruvilla</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Hemicrania Continua: a Clinical Perspective on Diagnosis and Management.</article-title>
            <source>Curr Neurol Neurosci Rep</source>
            <year>2018</year>
            <month>Oct</month>
            <day>17</day>
            <volume>18</volume>
            <issue>12</issue>
            <fpage>95</fpage>
            <pub-id pub-id-type="pmid">30328517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000e1;rate</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pereda</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Quintanilla</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Madera</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Increase in CGRP levels in a case of hemicrania continua normalizes after a successful response to galcanezumab.</article-title>
            <source>Neurol Sci</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>43</volume>
            <issue>7</issue>
            <fpage>4581</fpage>
            <page-range>4581-4582</page-range>
            <pub-id pub-id-type="pmid">35422108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eren</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Straube</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;berl</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schankin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Hemicrania Continua: Beneficial Effect of Non-Invasive Vagus Nerve Stimulation in a Patient With a Contraindication for Indomethacin.</article-title>
            <source>Headache</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>298</fpage>
            <page-range>298-301</page-range>
            <pub-id pub-id-type="pmid">27861830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trimboli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al-Kaisy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andreou</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lambru</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Non-invasive vagus nerve stimulation for the management of refractory primary chronic headaches: A real-world experience.</article-title>
            <source>Cephalalgia</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>1276</fpage>
            <page-range>1276-1285</page-range>
            <pub-id pub-id-type="pmid">28899205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Correia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lagrata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matharu</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>OnabotulinumtoxinA for hemicrania continua: open label experience in 9 patients.</article-title>
            <source>J Headache Pain</source>
            <year>2015</year>
            <month>Mar</month>
            <day>05</day>
            <volume>16</volume>
            <fpage>19</fpage>
            <pub-id pub-id-type="pmid">25902798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwedt</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Trentman</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Occipital nerve stimulation for chronic cluster headache and hemicrania continua: pain relief and persistence of autonomic features.</article-title>
            <source>Cephalalgia</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>8</issue>
            <fpage>1025</fpage>
            <page-range>1025-7</page-range>
            <pub-id pub-id-type="pmid">16886942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burns</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Treatment of medically intractable cluster headache by occipital nerve stimulation: long-term follow-up of eight patients.</article-title>
            <source>Lancet</source>
            <year>2007</year>
            <month>Mar</month>
            <day>31</day>
            <volume>369</volume>
            <issue>9567</issue>
            <fpage>1099</fpage>
            <page-range>1099-106</page-range>
            <pub-id pub-id-type="pmid">17398309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trentman</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Occipital nerve stimulation: technical and surgical aspects of implantation.</article-title>
            <source>Headache</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>319</fpage>
            <page-range>319-27</page-range>
            <pub-id pub-id-type="pmid">18234049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Franzini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Proietti Cecchini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mea</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Broggi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bussone</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Deep brain stimulation in trigeminal autonomic cephalalgias.</article-title>
            <source>Neurotherapeutics</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>220</fpage>
            <page-range>220-8</page-range>
            <pub-id pub-id-type="pmid">20430322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22718.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanayama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Namekawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sakiyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sugawara</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Herpes Zoster Ophthalmicus Initially Diagnosed As Cluster Headache, Complicated by Delayed Eruption.</article-title>
            <source>Cureus</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>e56698</fpage>
            <pub-id pub-id-type="pmid">38646210</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
